NCT07065630 is a Phase 2 clinical trial of Volrustomig in Head and Neck Cancer, sponsored by University of Chicago.

Who is sponsoring NCT07065630?

NCT07065630 is sponsored by University of Chicago.

What drugs are being tested in NCT07065630?

Interventions in NCT07065630: Volrustomig, Carboplatin, Paclitaxel.

What condition does NCT07065630 study?

NCT07065630 studies Head and Neck Cancer, HPV.

Is NCT07065630 still recruiting?

NCT07065630 is currently recruiting now. Last updated 4 March 2026.

Last reviewed 2026-03-04 · How we verify

NCT07065630

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

Recruiting now Phase 2 Last updated 4 March 2026

What this trial tests

Phase 2 trial testing Volrustomig in Head and Neck Cancer in 38 participants. Currently enrolling.

Timeline

7 October 2025

Primary endpoint
13 August 2029

13 August 2029

Quick facts

Lead sponsor	University of Chicago
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	7 October 2025
Primary completion	13 August 2029
Estimated completion	13 August 2029
Sites	1 location across United States

Drugs / interventions tested

Volrustomig — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
Paclitaxel — full drug profile →

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →
HPV — all drugs for HPV →

Sponsor

University of Chicago

Who can join

18 and older, any sex, with Head and Neck Cancer or HPV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and neck squamous cell carcinoma .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Volrustomig

Trials testing the same drug.

NCT07000149 — A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for · Phase 3 · active not recruiting
NCT06943833 — A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) · Phase 2 · active not recruiting
NCT06792695 — A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer · Phase 2 · recruiting
NCT06448754 — Volrustomig Priming Regimens Exploratory Phase II Platform Study · Phase 2 · recruiting
NCT06535607 — Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic · Phase 2 · recruiting

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other University of Chicago trials

Trials by the same sponsor.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07065630 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Chicago
Last refreshed: 4 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07065630.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing